The vaccine manufacturer has carried out trials to investigate the efficacy and safety of the product. The results of these studies show good protection against moderate and severe COVID-19 illness for the original virus variants. However, for the current virus variants, the level of protection is significantly reduced. We therefore recommend you receive an mRNA vaccine or the Novavax protein vaccine for your booster.
The vaccine also has a good safety profile. Serious side effects are very rare. A severe allergic reaction immediately after vaccination was experienced only in isolated cases. There were a few cases in which rare forms of thrombosis – in particular cerebral venous thrombosis or mesenteric (abdominal) venous thrombosis, but also arterial thromboses – were observed within the first three weeks after vaccination with the vector vaccine from Janssen. These events were serious but occurred very rarely (in between one and eight individuals per million). A causal relationship is thought to be plausible internationally.
Other than this, there have been no notable serious side effects to date. Specialists are observing the situation closely. The authorities and the manufacturers are also compiling data. The safety and efficacy of the vaccine are monitored continuously.
A vaccine must meet high safety, efficacy and quality standards before it can be authorised. In Switzerland, Swissmedic is responsible for authorisation: it decides whether a vaccine should be authorised. If Swissmedic is able to confirm the efficacy, safety and quality of the vaccine, it grants the marketing authorisation for Switzerland. The vector vaccine from Janssen fulfils these criteria. Swissmedic has authorised the vaccine.
You can find all the interim findings on the efficacy and safety of the vaccine on the Infovac website (available in German, French and Italian).